Literature DB >> 32482750

Keys to drug sensitivity from updated functional work flows.

Stephen E Kurtz1, Jeffrey W Tyner2,3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32482750      PMCID： PMC7271592          DOI： 10.3324/haematol.2020.250662

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

Review 1.  Stems cells and the pathways to aging and cancer.

Authors:  Derrick J Rossi; Catriona H M Jamieson; Irving L Weissman
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

2.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Authors:  Tea Pemovska; Mika Kontro; Bhagwan Yadav; Henrik Edgren; Samuli Eldfors; Agnieszka Szwajda; Henrikki Almusa; Maxim M Bespalov; Pekka Ellonen; Erkki Elonen; Bjørn T Gjertsen; Riikka Karjalainen; Evgeny Kulesskiy; Sonja Lagström; Anna Lehto; Maija Lepistö; Tuija Lundán; Muntasir Mamun Majumder; Jesus M Lopez Marti; Pirkko Mattila; Astrid Murumägi; Satu Mustjoki; Aino Palva; Alun Parsons; Tero Pirttinen; Maria E Rämet; Minna Suvela; Laura Turunen; Imre Västrik; Maija Wolf; Jonathan Knowles; Tero Aittokallio; Caroline A Heckman; Kimmo Porkka; Olli Kallioniemi; Krister Wennerberg
Journal:  Cancer Discov       Date:  2013-09-20       Impact factor: 39.397

3.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

Review 4.  Precision medicine for cancer with next-generation functional diagnostics.

Authors:  Adam A Friedman; Anthony Letai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Cancer       Date:  2015-11-05       Impact factor: 60.716

5.  Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.

Authors:  Muntasir M Majumder; Aino-Maija Leppä; Monica Hellesøy; Paul Dowling; Alina Malyutina; Reidun Kopperud; Despina Bazou; Emma Andersson; Alun Parsons; Jing Tang; Olli Kallioniemi; Satu Mustjoki; Peter O'Gorman; Krister Wennerberg; Kimmo Porkka; Bjørn T Gjertsen; Caroline A Heckman
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

6.  Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Authors:  Heikki Kuusanmäki; Aino-Maija Leppä; Petri Pölönen; Mika Kontro; Olli Dufva; Debashish Deb; Bhagwan Yadav; Oscar Brück; Ashwini Kumar; Hele Everaus; Bjørn T Gjertsen; Merja Heinäniemi; Kimmo Porkka; Satu Mustjoki; Caroline A Heckman
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

7.  Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.

Authors:  Shanshan Pei; Daniel A Pollyea; Annika Gustafson; Brett M Stevens; Mohammad Minhajuddin; Rui Fu; Kent A Riemondy; Austin E Gillen; Ryan M Sheridan; Jihye Kim; James C Costello; Maria L Amaya; Anagha Inguva; Amanda Winters; Haobin Ye; Anna Krug; Courtney L Jones; Biniam Adane; Nabilah Khan; Jessica Ponder; Jeffrey Schowinsky; Diana Abbott; Andrew Hammes; Jason R Myers; John M Ashton; Travis Nemkov; Angelo D'Alessandro; Jonathan A Gutman; Haley E Ramsey; Michael R Savona; Clayton A Smith; Craig T Jordan
Journal:  Cancer Discov       Date:  2020-01-23       Impact factor: 39.397
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.